Insmed Inc (INSM)

[copernicus]

"This is an orphan product...not a blockbuster." (not)

Wrong. The initial indication for which Insmed has orphan status is small, but there are other indications for the product that are much larger.

We also have BP3 which has applications in cancer treatment.

In addition, growth hormone is given to stimulate the production of IGF, so that's a large market that can be potentially addressed.

And the stock has gained over 40% on a monthly basis (intra-month high/prior month close) almost half the time over the last three years, so it's not speculative, and certainly not "stunningly speculative" to think that a catalyst like product launch will move the stock.

And finally, the guy whose post you dismissed as "stunningly speculative" didn't predict a price of $3, he said "hopefuly till then the price of the share will be above 3$." Not the same.